5 Low-Debt Biotech Stocks Forecasted For Growth
5 Low-Debt Biotech Stocks Forecasted For Growth Seeking Alpha
View ArticleDurata Therapeutics presents new efficacy review of dalbavancin
Durata Therapeutics presents new efficacy review of dalbavancin The Fly on the Wall
View Article2014 FDA Drug Approval Decision Calendar
2014 FDA Drug Approval Decision Calendar TheStreet.com
View ArticleKeep An Eye On GW, Johnson & Johnson, Durata, and Merck Today
Keep An Eye On GW, Johnson & Johnson, Durata, and Merck Today Motley Fool
View Article3 Biotechs With Major Catalysts Incoming
3 Biotechs With Major Catalysts Incoming Motley Fool
View ArticlePfizer Blockbuster Zyvox Under Attack
Pfizer Blockbuster Zyvox Under Attack Motley Fool
View ArticleHuge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing...
Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix Seeking Alpha
View ArticleFDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute...
FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults...
View ArticleCubist and Durata Heat Up Antibiotic Market
Cubist and Durata Heat Up Antibiotic Market Motley Fool
View ArticleInvesting to Fight Toilet and Elevator Superbugs
Investing to Fight Toilet and Elevator Superbugs Motley Fool
View ArticleDevice maker, drug company plunge by double digits on weak earnings
Device maker, drug company plunge by double digits on weak earnings Marketwatch
View ArticleIs Durata's Antibiotic Overpriced? A Twitter Conversation
Is Durata's Antibiotic Overpriced? A Twitter Conversation Forbes
View Article
